Our study retrospectively analyzed ctDNA from plasma samples of HER2-negative advanced GC patients who underwent immune checkpoint blockade therapies, revealing critical variations associated with treatment response, offering insights that could enhance the stratification of patients for more effective interventions. This evidence concerns the gene ERBB2 and gastric cancer.